中国全科医学2017，Vol.20Issue(6)：635-638,4.DOI:10.3969/j.issn.1007-9572.2017.06.001
2017. V1版《NCCN 结直肠癌诊治指南》更新解读
Interpretation of Updated NCCN Guidelines for Colon Cancer and Rectal Cancer(Version 1. 2017)
邵仟仟 1林国乐1
作者信息
- 1. 100730 北京市，中国医学科学院 北京协和医学院，北京协和医院基本外科
- 折叠
摘要
Abstract
This paper interpreted NCCN Guidelines for Colon Cancer and Rectal Cancer(Version 1. 2017). Compared with Version 2. 2016,the latest guideline made some significant updates,and the most important points included: (1) considering low - dose aspirin as the secondary chemoprevention for colorectal cancer(CRC)survivors;(2)in the first - line targeted therapy of RAS wide - type CRC(mCRC),EGFR inhibitors(cetuximab or panitumumab)should only be offered to patients whose primary tumors originated on the left side of the colon and rectum; ( 3 )the panel recommends against panitumumab and cetuximab in the neoadjuvant chemotherapy of resectable metastatic liver or lung neoplasms;(4)the panel recommends programmed death receptor - 1(PD - 1)inhibitors as treatment options in mCRC patients with metastatic deficient MMR(dMMR)or MSI - H in second - or third - line therapy.关键词
结直肠肿瘤/NCCN指南/2017.V1版更新Key words
Colorectal neoplasms/NCCN guideline/Updates in Version 1.2017分类
医药卫生引用本文复制引用
邵仟仟,林国乐..2017. V1版《NCCN 结直肠癌诊治指南》更新解读[J].中国全科医学,2017,20(6):635-638,4.
